<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id>
      <journal-id journal-id-type="publisher-id">CAS</journal-id>
      <journal-title-group>
        <journal-title>Cancer Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1347-9032</issn>
      <issn pub-type="epub">1349-7006</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27193600</article-id>
      <article-id pub-id-type="pmc">4982591</article-id>
      <article-id pub-id-type="doi">10.1111/cas.12970</article-id>
      <article-id pub-id-type="publisher-id">CAS12970</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>New variant of acute promyelocytic leukemia with <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic> fusion</article-title>
        <alt-title alt-title-type="left-running-head">Shimomura <italic>et&#xA0;al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="cas12970-cr-0001" contrib-type="author">
          <name>
            <surname>Shimomura</surname>
            <given-names>Yoshimitsu</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0002" contrib-type="author" corresp="yes">
          <name>
            <surname>Mitsui</surname>
            <given-names>Hideki</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0003" contrib-type="author">
          <name>
            <surname>Yamashita</surname>
            <given-names>Yukiko</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0004" contrib-type="author">
          <name>
            <surname>Kamae</surname>
            <given-names>Tsuyoshi</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0005" contrib-type="author">
          <name>
            <surname>Kanai</surname>
            <given-names>Akinori</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0006" contrib-type="author">
          <name>
            <surname>Matsui</surname>
            <given-names>Hirotaka</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0007" contrib-type="author">
          <name>
            <surname>Ishibashi</surname>
            <given-names>Tomohiko</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0008" contrib-type="author">
          <name>
            <surname>Tanimura</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0009" contrib-type="author">
          <name>
            <surname>Shibayama</surname>
            <given-names>Hirohiko</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0010" contrib-type="author">
          <name>
            <surname>Oritani</surname>
            <given-names>Kenji</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0011" contrib-type="author">
          <name>
            <surname>Kuyama</surname>
            <given-names>Jun</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cas12970-cr-0012" contrib-type="author">
          <name>
            <surname>Kanakura</surname>
            <given-names>Yuzuru</given-names>
          </name>
          <xref ref-type="aff" rid="cas12970-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="cas12970-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Hematology</named-content>
        <institution>Kobe City Hospital Organization Kobe City Medical Center General Hospital</institution>
        <named-content content-type="city">Kobe</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas12970-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Department of Hematology</named-content>
        <institution>Otemae Hospital</institution>
        <named-content content-type="city">Osaka</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas12970-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Research Institute for Radiation Biology and Medicine</named-content>
        <institution>Hiroshima University</institution>
        <named-content content-type="city">Hiroshima</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas12970-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of General Internal Medicine</named-content>
        <institution>Kumamoto University</institution>
        <named-content content-type="city">Kumamoto</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas12970-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Department of Hematology and Oncology</named-content>
        <institution>Osaka University</institution>
        <named-content content-type="city">Suita</named-content>
        <country country="JP">Japan</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hideki Mitsui, Department of Hematology, Otemae Hospital, 1&#x2010;5&#x2010;34, Otemae, Chuou&#x2010;ku, Osaka, Osaka 540&#x2010;0008, Japan.<break/>
Tel: +81&#x2010;6&#x2010;6941&#x2010;0484; Fax: +81&#x2010;6&#x2010;6942&#x2010;2848;<break/>
E&#x2010;mail: <email>drmitsui@otemae.gr.jp</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <volume>107</volume>
      <issue>8</issue>
      <issue-id pub-id-type="doi">10.1111/cas.2016.107.issue-8</issue-id>
      <fpage>1165</fpage>
      <lpage>1168</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 Japanese Cancer Association <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2016 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x2010;NonCommercial&#x2010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-107-1165.pdf"/>
      <abstract id="cas12970-abs-0001">
        <p>We present an acute promyelocytic leukemia (<styled-content style="fixed-case">APL</styled-content>) patient with two subtypes of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic>, in which the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> gene showed completely new breakpoints. Bone marrow examination revealed morphologic features indicative of <styled-content style="fixed-case">APL</styled-content>. However, promyelocytic leukemia<italic>&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic> fusion was not detected. A paired&#x2010;end <styled-content style="fixed-case">mRNA</styled-content> sequencing followed by <styled-content style="fixed-case">RT</styled-content>&#x2010;<styled-content style="fixed-case">PCR</styled-content> and direct sequencing revealed two types of fusion transcripts between exon 1B of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> and exon 3 of <italic><styled-content style="fixed-case">RARA</styled-content></italic>. The patient received all&#x2010;trans retinoic acid and conventional chemotherapy, but showed resistance. This is the second report of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> involvement in <styled-content style="fixed-case">APL</styled-content>, and we describe various breakpoints for the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic> fusion gene.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="cas12970-kwd-0001">Acute promyelocytic leukemia</kwd>
        <kwd id="cas12970-kwd-0002">all&#x2010;trans retinoic acid</kwd>
        <kwd id="cas12970-kwd-0003">fluorescence <italic>in&#xA0;situ</italic> hybridization</kwd>
        <kwd id="cas12970-kwd-0004">gemtuzumab ozogamicin</kwd>
        <kwd id="cas12970-kwd-0005">interferon regulatory protein 2 binding protein 2</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Takeda Pharmaceutical Co., Ltd.</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Sumitomo Dainippon Pharma</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Asahi Kasei Pharma</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Shionogi Co., Ltd.</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Yakult Pharmaceutical Industry Co., Ltd.</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="4"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>cas12970</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>August 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:12.08.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas12970-cit-1001">
<source>Cancer Sci</source>
<volume>107</volume> (<year>2016</year>) <fpage>1165</fpage>&#x2013;<lpage>1168</lpage>
</mixed-citation>
</p>
    </notes>
    <notes>
      <fn-group id="cas12970-ntgp-0001">
        <fn id="cas12970-note-1001">
          <p>
<bold>Funding Information</bold>
</p>
          <p>Takeda Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharma; Asahi Kasei Pharma; Shionogi Co., Ltd.; Yakult Pharmaceutical Industry Co., Ltd.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <p>Acute promyelocytic leukemia (APL) is an acute myeloid leukemia subtype characterized by promyelocytes with abnormal morphology, coagulopathy, specific chromosomal abnormalities, and unique response to retinoic acid treatment. Most APL patients carry t(15;17)(q22;q12), which results from the fusion of the promyelocytic leukemia (<italic>PML</italic>) and retinoic acid receptor &#x3B1; (<italic>RARA</italic>) genes.<xref rid="cas12970-bib-0001" ref-type="ref">1</xref> Consequently, the retinoid sensitivity of <italic>RARA</italic> is reduced, blocking myeloid differentiation. Other fusion partners of <italic>RARA</italic> have been found.<xref rid="cas12970-bib-0002" ref-type="ref">2</xref>, <xref rid="cas12970-bib-0003" ref-type="ref">3</xref>, <xref rid="cas12970-bib-0004" ref-type="ref">4</xref>, <xref rid="cas12970-bib-0005" ref-type="ref">5</xref>, <xref rid="cas12970-bib-0006" ref-type="ref">6</xref>, <xref rid="cas12970-bib-0007" ref-type="ref">7</xref>, <xref rid="cas12970-bib-0008" ref-type="ref">8</xref>, <xref rid="cas12970-bib-0009" ref-type="ref">9</xref> Recently, interferon regulatory protein 2 binding protein 2 (<italic>IRF2BP2</italic>) emerged as a new <italic>RARA</italic> partner; this <italic>IRF2BP2&#x2013;RARA</italic> fusion gene includes exon 2 of <italic>IRF2BP2</italic> and intron 2 of <italic>RARA</italic>.<xref rid="cas12970-bib-0010" ref-type="ref">10</xref>
</p>
    <p>Herein, we describe the second case of APL with the <italic>IRF2BP2&#x2013;RARA</italic> fusion gene, in which novel breakpoints in <italic>IRF2BP2</italic> and unique clinical characteristics were noted.</p>
    <sec id="cas12970-sec-0002">
      <title>Case</title>
      <p>A 68&#x2010;year&#x2010;old Japanese woman was admitted to Otemae Hospital (Osaka City, Japan) with pancytopenia in May 2012. Initial complete blood counts showed: hemoglobin, 8.2&#xA0;g/dL; platelets, 48&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L; and white blood cells, 1.65&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L (including 1% promyelocytes). No disseminated intravascular coagulation (DIC) was detected. A bone marrow sample showed marked hypercellularity; 36.8% were promyelocytes with azurophilic granules and Auer rods (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>a). Flow cytometry revealed APL cells positive for cluster of differentiation (CD) 33, CD34, CD64, CD117, and human leukocyte antigen (HLA)&#x2010;DR, and negative for CD2, CD7, CD13, and CD19. Fluorescence <italic>in&#xA0;situ</italic> hybridization (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>b) and RT&#x2010;PCR failed to detect <italic>PML&#x2013;RARA</italic> fusion, and chromosomal examination of leukemia cells showed &#x2013;X. Fluorescence <italic>in&#xA0;situ</italic> hybridization with dual fusion translocation probes detected no typical <italic>RARA</italic> split signals, but rather a small <italic>RARA</italic> signal and two large signals (46/100) (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>c). Accordingly, the patient was diagnosed with APL, and remission induction therapy was initiated with all&#x2010;trans retinoic acid (ATRA; 45&#xA0;mg/m<sup>2</sup>/day). On day 12, promyelocytes in the peripheral blood increased to &gt;10&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L; therefore, we added idarubicin (9&#xA0;mg/m<sup>2</sup>/day from days 12 to 14) and cytosine arabinoside (75&#xA0;mg/m<sup>2</sup>/day from days 12 to 18). However, complete remission (CR) was not achieved. Re&#x2010;induction therapy was initiated with gemtuzumab ozogamicin (GO) (9&#xA0;mg/m<sup>2</sup>) because of high CD33 expression. One month later, morphological examination and FISH of bone marrow aspirate showed hematological remission. In April 2013, the patient experienced molecular relapse as determined by an increase of Wilms tumor&#x2010;1 mRNA in the peripheral blood. She was re&#x2010;administered with GO (9&#xA0;mg/m<sup>2</sup>), and remained in hematological remission until August 2013 when she developed syncope. Magnetic resonance images revealed several enhanced regions in the right brain, and her cerebrospinal fluid (CSF) clearly contained APL cells. Because her level of consciousness was depressed despite high&#x2010;dose methotrexate and cytarabine infusion, whole brain irradiation was undertaken. One month later, her neurological symptoms disappeared, and her CSF cytology revealed no APL cells. In February 2014, she developed bilateral leg weakness and walking difficulty. Lumbar magnetic resonance imaging showed enhancement in the conus and nerve roots, and APL cells were once again detected in her CSF. Craniospinal irradiation was undertaken, and her symptoms disappeared temporarily. However, she relapsed in August 2014 and died of APL.</p>
      <fig fig-type="Figure" xml:lang="en" id="cas12970-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Morphological, cytogenetic, and molecular features of a bone marrow sample from a 68&#x2010;year&#x2010;old Japanese woman with acute promyelocytic leukemia. (a) May&#x2013;Giemsa staining. Promyelocytes with azurophilic granules and Auer rods are observed. (b) Interphase <styled-content style="fixed-case">FISH</styled-content> using promyelocytic leukemia (<italic><styled-content style="fixed-case">PML</styled-content></italic>) (15q22; green) and retinoic acid receptor &#x3B1; (<italic><styled-content style="fixed-case">RARA</styled-content></italic>) (17q21; red) probes did not reveal a <italic><styled-content style="fixed-case">PML</styled-content>&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic> fusion signal (yellow). (c) Interphase <styled-content style="fixed-case">FISH</styled-content> assay to detect <italic><styled-content style="fixed-case">RARA</styled-content></italic> split signal (using 3&#x2032;&#x2010;<italic><styled-content style="fixed-case">RARA</styled-content></italic> [green] and 5&#x2032;&#x2010;<italic><styled-content style="fixed-case">RARA</styled-content></italic> [red] probes) showed no split signals but rather a small yellow signal (46/100; arrow). (d) <styled-content style="fixed-case">mRNA</styled-content> expression of interferon regulatory factor 2 binding protein 2 (<italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic>) and <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic>. Lane 1 shows the result of using two complementary oligonucleotide primers, <styled-content style="fixed-case">FP</styled-content>1 and <styled-content style="fixed-case">RP</styled-content>1. The upper detected band was predicted to be 206&#xA0;bp and the lower band was predicted to be 158&#xA0;bp; these bands were supposed to correspond to the expression of normal splice variants of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> in the patient's bone marrow. Lane 2 shows the result of <styled-content style="fixed-case">FP</styled-content>1 and <styled-content style="fixed-case">RP</styled-content>2. The upper detected band was predicted to be 398&#xA0;bp and the lower band was predicted to be 350&#xA0;bp; these bands were supposed to correspond to the expression of the fusion variants of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic>. (e) Direct sequencing of the <styled-content style="fixed-case">PCR</styled-content> products. The sequences of each <styled-content style="fixed-case">PCR</styled-content> product obtained in (d) were determined. The results confirmed that this patient expressed two variants of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> (data not shown), as well as the predicted fusion <styled-content style="fixed-case">mRNA</styled-content>s of <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic>; the upper and lower panels show the sequences of the fusion genes from <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> variants 1 and 2, respectively. (f) Schematic illustrations of the transcripts. The blue and yellow solid bars represent the coding regions of the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> and <italic><styled-content style="fixed-case">RARA</styled-content></italic> genes, respectively. <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> generates the transcript variants through alternative splicing. Variant 1 uses an alternate in&#x2010;frame splice junction in the 3&#x2032;&#x2010; coding region of exon 1, resulting in an <styled-content style="fixed-case">mRNA</styled-content> transcript 48&#xA0;bp longer than variant 2. The inverted triangles represent each predicted fusion point on the transcript. The <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;<styled-content style="fixed-case">RARA</styled-content></italic> fusion is expected to generate two types of fusion <styled-content style="fixed-case">mRNA</styled-content> depending on the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic> variants. In the longer type, base 1079 of the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2 </italic>
<styled-content style="fixed-case">mRNA</styled-content> is likely to be fused to base 769 of the <italic><styled-content style="fixed-case">RARA</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. In the shorter type, the base 1031 of the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2 </italic>
<styled-content style="fixed-case">mRNA</styled-content> is likely to be fused to base 769 of the <italic><styled-content style="fixed-case">RARA</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. (g) Overviews of genomic <styled-content style="fixed-case">DNA</styled-content> of the <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2</italic>,<italic><styled-content style="fixed-case">RARA</styled-content></italic>, and predicted <italic><styled-content style="fixed-case">IRF</styled-content>2<styled-content style="fixed-case">BP</styled-content>2&#x2013;RARA</italic> fusion genes.</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="CAS-107-1165-g001"/>
      </fig>
      <p>After obtaining written informed consent and institutional review board approval, paired&#x2010;end mRNA sequencing was carried out to identify the fusion gene partner of <italic>RARA</italic>. Consequently, we identified a chromosomal translocation between chr.1q42.3 and 17q21.2. This translocation gives rise to a putative fusion protein comprising exon 1 of <italic>IRF2BP2</italic> and exons 3&#x2013;9 of <italic>RARA</italic>. <italic>IRF2BP2</italic> comprises two exons with an intron, and there are two splicing sites within <italic>IRF2BP2</italic> exon 1. Accordingly, we generated primer pairs to amplify the cDNAs of <italic>IRF2BP2</italic> (FP and RP1) and <italic>IRF2BP2&#x2013;RARA</italic> (FP and RP2). This primer information is shown in Appendix&#xA0;S1. As predicted, two fragments were amplified by RT&#x2010;PCR for both <italic>IRF2BP2</italic> and <italic>IRF2BP2&#x2013;RARA</italic> (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>d). The PCR product sequences corresponded well to the splicing sites (at the 1031 and 1079&#xA0;bp positions of <italic>IRF2BP2</italic> cDNA) (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>e). The <italic>RARA</italic> transcript started at the beginning of exon 3 (at 769&#xA0;bp of <italic>RARA</italic> cDNA). Thus, our additional mRNA analysis clearly indicated that the IRF2BP2&#x2013;RARA fusion proteins showed variant forms that were dependent on <italic>IRF2BP2</italic> splicing. The transcript structures for <italic>IRF2BP2</italic> and <italic>RARA</italic>, as well as <italic>IRF2BP2&#x2013;RARA</italic>, are shown in Figure&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>f. Taken together, the <italic>IRF2BP2&#x2013;RARA</italic> gene is likely to be positioned between intron 1 of <italic>IRF2BP2</italic> and intron 2 of <italic>RARA</italic> (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>g).</p>
    </sec>
    <sec id="cas12970-sec-0003">
      <title>Discussion</title>
      <p>To our knowledge, this is the second report of a novel APL variant with <italic>IRF2BP2&#x2010;RARA</italic>; this case uniquely showed atypical morphological and clinical features with no DIC detected at admission.</p>
      <p>Flow cytometry is a powerful ancillary tool for diagnosing APL. Classic APL cells with <italic>PML&#x2013;RARA</italic> typically express mature myeloid markers, including CD13 and CD33, and are negative for CD34 and HLA&#x2010;DR. Moreover, several reports have shown expression of CD34 and/or HLA&#x2010;DR in a significant proportion of newly diagnosed APL patients.<xref rid="cas12970-bib-0011" ref-type="ref">11</xref>, <xref rid="cas12970-bib-0012" ref-type="ref">12</xref>, <xref rid="cas12970-bib-0013" ref-type="ref">13</xref> In our case, the APL cells were positive for CD33, CD34, CD64, CD117, and HLA&#x2010;DR, and negative for CD2, CD7, CD13, and CD19.</p>
      <p>Fluorescence <italic>in&#xA0;situ</italic> hybridization with dual fusion translocation probes is useful for detecting unknown rearrangements of the <italic>RARA</italic> gene.<xref rid="cas12970-bib-0014" ref-type="ref">14</xref> Herein, we failed to detect <italic>PML&#x2013;RARA</italic> fusion; however, use of a <italic>RARA</italic> dual fusion translocation probe allowed us to detect a novel rearrangement of the <italic>RARA</italic> gene. Cases of APL with cryptic <italic>PML&#x2013;RARA</italic> rearrangement that were negative by FISH and conventional karyotyping but positive by RT&#x2010;PCR have been reported;<xref rid="cas12970-bib-0015" ref-type="ref">15</xref> these findings were caused by small cryptic insertions. Abnormal FISH and normal karyotyping also suggested small cryptic insertions in our case. A normal yellow signal indicated normal 17q while another indicated a small deletion in 17q; furthermore, an abnormal small yellow signal indicated a small insertion of RARA (Fig.&#xA0;<xref rid="cas12970-fig-0001" ref-type="fig">1</xref>).</p>
      <p>The <italic>IRF2BP2</italic>&#x2013;<italic>CDX&#x2010;1</italic> fusion gene has been reported in mesenchymal chondrosarcoma,<xref rid="cas12970-bib-0016" ref-type="ref">16</xref> and there is one previous report of <italic>IRF2BP2&#x2013;RARA</italic> in APL.<xref rid="cas12970-bib-0010" ref-type="ref">10</xref> Yin <italic>et&#xA0;al</italic>.<xref rid="cas12970-bib-0010" ref-type="ref">10</xref> reported a case of APL with <italic>IRF2BP2&#x2013;RARA</italic> that involved exon 2 of <italic>IRF2BP2</italic> and intron 2 of <italic>RARA</italic>, with breakpoints at positions 1687&#xA0;bp in <italic>IRF2BP2</italic> and 41620&#xA0;bp in <italic>RARA</italic>. The patient achieved CR with ATRA, arsenic trioxide, and GO; however, relapse occurred 2&#xA0;months after consolidation therapy. Herein, <italic>IRF2BP2</italic> showed distinct breakpoints, and two subtypes of <italic>IRF2BP2&#x2013;RARA</italic> were noted. Our case differed in its atypical morphology and clinical course, as well as the lack of DIC on admission. Tissue factors and cancer procoagulant expressed in APL cells are associated with DIC; the lack of DIC in our case may be explained by the lower number of APL cells compared to that in the previously reported patient. Most patients with APL can achieve CR with ATRA with or without anthracycline, resulting in favorable clinical outcomes.<xref rid="cas12970-bib-0017" ref-type="ref">17</xref>, <xref rid="cas12970-bib-0018" ref-type="ref">18</xref>, <xref rid="cas12970-bib-0019" ref-type="ref">19</xref> In the previous <italic>IRF2BP2&#x2013;RARA</italic> case, clinical sensitivity to ATRA was not properly evaluated because of combination therapy with arsenic trioxide and GO. Our patient did not respond to ATRA monotherapy. In the presence of pharmacological concentrations of ATRA, transcriptional activation can be induced by dissociation of the co&#x2010;repressor complex from PML&#x2013;RARA as well as proteasome&#x2010;dependent PML&#x2013;RARA degradation. In cases with ligand binding domain mutations in the <italic>RARA</italic> gene, ATRA fails to recognize RARA, and co&#x2010;repressor dissociation does not occur, resulting in ATRA resistance.<xref rid="cas12970-bib-0014" ref-type="ref">14</xref> Other fusion genes such as <italic>PLZF&#x2013;RARA</italic>
<xref rid="cas12970-bib-0005" ref-type="ref">5</xref> and <italic>STAT5b&#x2013;RARA</italic>
<xref rid="cas12970-bib-0020" ref-type="ref">20</xref> also show ATRA resistance. The Nuclear receptor corepressor (N&#x2010;CoR)/Silencing mediator for retinoid and thyroid hormone receptors (SMRT) co&#x2010;repressor complex interaction with <italic>PLZF</italic> and <italic>STAT5b</italic> translocation is thought to be involved in this resistance. IRF2BP2 also interacts with N&#x2010;CoR co&#x2010;repressor proteins;<xref rid="cas12970-bib-0021" ref-type="ref">21</xref> we speculated that IRF2BP2&#x2013;RARA is involved in ATRA resistance because of this.</p>
      <p>In conclusion, we described a case of APL with <italic>IRF2BP2&#x2013;RARA</italic> involving exon 1B of <italic>IRF2BP2</italic>. The patient had some peculiar clinical characteristics, such as no coagulopathy, a unique cell surface phenotype, and ATRA resistance. Although APL with <italic>IRF2BP2&#x2013;RARA</italic> is rarely observed, its unique characteristics have clinical implications for the diagnosis and treatment of APL patients.</p>
    </sec>
    <sec id="cas12970-sec-0005">
      <title>Disclosure Statement</title>
      <p>The authors have no conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Appendix&#xA0;S1</bold> Primer information for amplification of cDNAs of <italic>IRF2BP2</italic> (FP and RP1) and <italic>IRF2BP2&#x2013;RARA</italic> (FP and RP2).</p>
        </caption>
        <media xlink:href="CAS-107-1165-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="cas12970-sec-0004">
      <title>Acknowledgments</title>
      <p>The authors thank the medical and nursing staff at Otemae Hospital.</p>
    </ack>
    <ref-list content-type="cited-references" id="cas12970-bibl-0001">
      <title>References</title>
      <ref id="cas12970-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0001">
<string-name>
<surname>de Th&#xE9;</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chomienne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lanotte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Degos</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dejean</surname>
<given-names>A</given-names>
</string-name>. <article-title>The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus</article-title>. <source>Nature</source>
<year>1990</year>; <volume>347</volume>: <fpage>558</fpage>&#x2013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">2170850</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0002">
<string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Brand</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>A</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Fusion between a novel Kruppel&#x2010;like zinc finger gene and the retinoic acid receptor&#x2010;alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia</article-title>. <source>EMBO J</source>
<year>1993</year>; <volume>12</volume>: <fpage>1161</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8384553</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0003">
<string-name>
<surname>Redner</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Faas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rudert</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Corey</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin&#x2010;retinoic acid receptor fusion</article-title>. <source>Blood</source>
<year>1996</year>; <volume>87</volume>: <fpage>882</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8562957</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0004">
<string-name>
<surname>Wells</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Catzavelos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kamel&#x2010;Reid</surname>
<given-names>S</given-names>
</string-name>. <article-title>Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia</article-title>. <source>Nat Genet</source>
<year>1997</year>; <volume>17</volume>: <fpage>109</fpage>&#x2013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">9288109</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0005">
<string-name>
<surname>Arnould</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Philippe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bourdon</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gr&#xE9;goire</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jonveaux</surname>
<given-names>P</given-names>
</string-name>. <article-title>The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic&#x2010;like leukaemia</article-title>. <source>Hum Mol Genet</source>
<year>1999</year>; <volume>8</volume>: <fpage>1741</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10441338</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0006">
<string-name>
<surname>Catalano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Somana</surname>
<given-names>K</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia</article-title>. <source>Blood</source>
<year>2007</year>; <volume>110</volume>: <fpage>4073</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17712046</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0007">
<string-name>
<surname>Kondo</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Darmanin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hashino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Asaka</surname>
<given-names>M</given-names>
</string-name>. <article-title>The seventh pathogenic fusion gene FIP1L1&#x2010;RARA was isolated from a t(4;17)&#x2010;positive acute promyelocytic leukemia</article-title>. <source>Haematologica</source>
<year>2008</year>; <volume>93</volume>: <fpage>1414</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18603554</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0008">
<string-name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tsuzuki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsuzuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Handa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Inaguma</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Emi</surname>
<given-names>N</given-names>
</string-name>. <article-title>BCOR&#xA0;as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia</article-title>. <source>Blood</source>
<year>2010</year>; <volume>116</volume>: <fpage>4274</fpage>&#x2013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">20807888</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0009">
<string-name>
<surname>Won</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>CJ</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia</article-title>. <source>Blood</source>
<year>2013</year>; <volume>121</volume>: <fpage>1432</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23287866</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0010">
<string-name>
<surname>Yin</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Jain</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mehrotra</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Identification of a novel fusion gene, IRF2BP2&#x2010;RARA, in acute promyelocytic leukemia</article-title>. <source>J Natl Compr Canc Netw</source>
<year>2015</year>; <volume>13</volume>: <fpage>19</fpage>&#x2013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25583766</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0011">
<string-name>
<surname>Stasi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bruno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Venditti</surname>
<given-names>A</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>A microgranular variant of acute promyelocytic leukemia with atypical morpho&#x2010;cytochemical features and an early myeloid immunophenotype</article-title>. <source>Leuk Res</source>
<year>1997</year>; <volume>21</volume>: <fpage>575</fpage>&#x2013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">9279368</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0012">
<string-name>
<surname>Thalhammer&#x2010;Scherrer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mitterbauer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Simonitsch</surname>
<given-names>I</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination</article-title>. <source>Am J Clin Pathol</source>
<year>2002</year>; <volume>117</volume>: <fpage>380</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11888077</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0013">
<string-name>
<surname>Lin</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Medeiros</surname>
<given-names>LJ</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML&#x2010;RARalpha transcripts and poorer prognosis</article-title>. <source>Am J Clin Pathol</source>
<year>2004</year>; <volume>121</volume>: <fpage>402</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15023045</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0014">
<string-name>
<surname>Goto</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tomita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hayakawa</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Atsumi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kiyoi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Naoe</surname>
<given-names>T</given-names>
</string-name>. <article-title>Missense mutations in PML&#x2010;RARA are critical for the lack of responsiveness to arsenic trioxide treatment</article-title>. <source>Blood</source>
<year>2011</year>; <volume>118</volume>: <fpage>1600</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21613260</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0015">
<string-name>
<surname>Kim</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>MH</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>FISH&#x2010;negative cryptic PML&#x2010;RARA rearrangement detected by long&#x2010;distance polymerase chain reaction and sequencing analyses: a case study and review of the literature</article-title>. <source>Cancer Genet Cytogenet</source>
<year>2010</year>; <volume>203</volume>: <fpage>278</fpage>&#x2013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">21156244</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0016">
<string-name>
<surname>Nyquist</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Panagopoulos</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Thorsen</surname>
<given-names>J</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Whole&#x2010;transcriptome sequencing identifies novel IRF2BP2&#x2010;CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma</article-title>. <source>PLoS ONE</source>
<year>2012</year>; <volume>7</volume>: <fpage>e49705</fpage>.<pub-id pub-id-type="pmid">23185413</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0017">
<string-name>
<surname>Frankel</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Eardley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lauwers</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Warrell</surname>
<given-names>RP</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>The &#x201C;retinoic acid syndrome&#x201D; in acute promyelocytic leukemia</article-title>. <source>Ann Intern Med</source>
<year>1992</year>; <volume>117</volume>: <fpage>292</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">1637024</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0018">
<string-name>
<surname>Lo</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Nervi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Avvisati</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mandelli</surname>
<given-names>F</given-names>
</string-name>. <article-title>Acute promyelocytic leukemia: a curable disease</article-title>. <source>Leukemia</source>
<year>1998</year>; <volume>12</volume>: <fpage>1866</fpage>&#x2013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">9844917</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0019">
<string-name>
<surname>Tallman</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Nabhan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Feusner</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Acute promyelocytic leukemia: evolving therapeutic strategies</article-title>. <source>Blood</source>
<year>2002</year>; <volume>99</volume>: <fpage>759</fpage>&#x2013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">11806975</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0020">
<string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Guidez</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rousselot</surname>
<given-names>P</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>PLZF&#x2010;RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand&#x2010;dependent transactivation of wild&#x2010;type retinoic acid receptors</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1994</year>; <volume>91</volume>: <fpage>1178</fpage>&#x2013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">8302850</pub-id></mixed-citation>
      </ref>
      <ref id="cas12970-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="cas12970-cit-0021">
<string-name>
<surname>Stadhouders</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cico</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stephen</surname>
<given-names>T</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Control of developmentally primed erythroid genes by combinatorial co&#x2010;repressor actions</article-title>. <source>Nat Commun</source>
<year>2015</year>; <volume>6</volume>: <fpage>8893</fpage>.<pub-id pub-id-type="pmid">26593974</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
